Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Response to bortezomib of a patient with scleromyxedema refractory to other therapies.

Migkou M, Gkotzamanidou M, Terpos E, Dimopoulos MA, Kastritis E.

Leuk Res. 2011 Nov;35(11):e209-11. doi: 10.1016/j.leukres.2011.07.021. Epub 2011 Aug 9. No abstract available.

PMID:
21831425
2.

Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.

Fett NM, Toporcer MB, Dalmau J, Shinohara MM, Vogl DT.

Am J Hematol. 2011 Oct;86(10):893-6. No abstract available.

PMID:
22026006
3.

Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.

Yeung CK, Loong F, Kwong YL.

Br J Haematol. 2012 May;157(4):411. doi: 10.1111/j.1365-2141.2012.09088.x. Epub 2012 Mar 19. No abstract available.

PMID:
22429092
5.

Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.

Hourigan CS, Forde PM, Ambinder RF, Gladstone DE.

Leuk Lymphoma. 2013 Nov;54(11):2563-4. doi: 10.3109/10428194.2013.780289. Epub 2013 Apr 19. No abstract available.

6.

Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.

Mateos-Mazon J, Pérez-Simón JA, Lopez O, Hernández E, Etxebarria J, San Miguel JF.

Haematologica. 2007 Sep;92(9):1295-6.

7.

Scleromyxedema.

Hummers LK.

Curr Opin Rheumatol. 2014 Nov;26(6):658-62. doi: 10.1097/BOR.0000000000000118. Review.

PMID:
25215418
8.

Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.

Mele G, Pinna S, Alloro E, Brocca MC, Coppi MR, Quarta G.

Leuk Res. 2007 May;31(5):721-3. Epub 2006 Aug 4. No abstract available.

PMID:
16890285
9.

Bortezomib therapy following first relapse.

Orlowski RZ; Multiple Myeloma Research Foundation.

Oncology (Williston Park). 2005 Jan;19(1):23-6. No abstract available.

PMID:
15743149
10.

Skin lesions induced by bortezomib.

Pour L, Hajek R, Zdenek A, Krejci M, Krivanova A, Vorlicek J.

Haematologica. 2005 Dec;90(12 Suppl):ECR44.

11.

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

Kuroda J, Kobayashi T, Tsutsumi Y, Yamamoto M, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M.

Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27. No abstract available.

PMID:
20978877
12.

[Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].

Xu JJ, Hu XH, Shen YY.

Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):697-8. Chinese. No abstract available.

PMID:
22339831
13.

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.

Cancer. 2006 Mar 15;106(6):1316-9.

14.

Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.

Grassinger J, Südhoff T, Andreesen R, Hennemann B.

Ann Hematol. 2006 Feb;85(2):132-3. Epub 2005 Nov 26. No abstract available.

PMID:
16311736
15.

Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.

Zangari M, Guerrero J, Cavallo F, Prasad HK, Esseltine D, Fink L.

Haematologica. 2008 Jun;93(6):953-4. doi: 10.3324/haematol.12522. No abstract available.

16.

Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.

Chim CS, Ooi GC, Loong F, Au AW, Lie AK.

J Clin Oncol. 2005 Apr 1;23(10):2426-8. No abstract available.

PMID:
15800336
17.

Medullary renal cell carcinoma and response to therapy with bortezomib.

Ronnen EA, Kondagunta GV, Motzer RJ.

J Clin Oncol. 2006 Mar 20;24(9):e14. No abstract available.

PMID:
16549825
18.

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.

Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC.

Br J Haematol. 2009 Nov;147(4):531-4. doi: 10.1111/j.1365-2141.2009.07875.x. Epub 2009 Sep 1.

PMID:
19725827
19.

Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.

Fröhlich K, Holle JU, Aries PM, Gross WL, Moosig F.

Ann Rheum Dis. 2011 Jul;70(7):1344-5. doi: 10.1136/ard.2010.133256. Epub 2010 Dec 20. No abstract available.

PMID:
21173019
20.

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.

Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K, Horvath N, Roberts AW, Prince HM, Hertzberg M, McLean CA, Spencer A.

Clin Cancer Res. 2009 Jan 15;15(2):714-22. doi: 10.1158/1078-0432.CCR-08-1022.

Supplemental Content

Support Center